MNG673
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.370
- SPERMATOGENESIS+0.226
- G2M_CHECKPOINT+0.222
- MITOTIC_SPINDLE+0.220
- MYC_TARGETS_V2+0.209
- WNT_BETA_CATENIN_SIGNALING+0.125
- ANDROGEN_RESPONSE+0.110
- UNFOLDED_PROTEIN_RESPONSE+0.110
- E2F_TARGETS+0.088
- BILE_ACID_METABOLISM+0.084
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.490
- INTERFERON_GAMMA_RESPONSE-0.453
- TNFA_SIGNALING_VIA_NFKB-0.442
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- IL6_JAK_STAT3_SIGNALING-0.388
- ALLOGRAFT_REJECTION-0.378
- INFLAMMATORY_RESPONSE-0.323
- CHOLESTEROL_HOMEOSTASIS-0.298
- P53_PATHWAY-0.282
- KRAS_SIGNALING_UP-0.275
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E9-A1R7-01A-11R-A14M-07 | — | B | 0.868 |
| 2 | 2e15a781-21c1-421b-9e92-6d2d414e0d14 | — | — | 0.857 |
| 3 | TCGA-D8-A1XR-01A-11R-A14M-07 | — | B | 0.854 |
| 4 | TCGA-BH-A0HL-01A-11R-A10U-07 | — | B | 0.851 |
| 5 | TCGA-E2-A15T-01A-11R-A115-07 | — | B | 0.849 |
| 6 | TCGA-C8-A12M-01A-11R-A115-07 | — | B | 0.847 |
| 7 | TCGA-A7-A3IZ-01A-11R-A213-07 | — | B | 0.847 |
| 8 | MNG239 | — | — | 0.845 |
| 9 | TCGA-E2-A15R-01A-11R-A115-07 | — | B | 0.844 |
| 10 | e8db6fe2-7a97-4f20-a7e0-9600f0e58800 | — | — | 0.837 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.226 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.222 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.209 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.125 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.110 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.110 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.088 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.084 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.082 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.078 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.058 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.058 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.053 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.047 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.029 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.012 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.011 | Idelalisib | — uncovered |